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In this study, we assessed the antileishmanial activity of 126 ,-unsaturated ketones. The compounds NC901, NC884, and
NC2459 showed high leishmanicidal activity for both the extracellular (50% effective concentration [EC50], 456 nM, 1,122 nM,
and 20 nM, respectively) and intracellular (EC50, 1,870 nM, 937 nM, and 625 nM, respectively) forms of Leishmania major prop-
agated in macrophages, with little or no toxicity to mammalian cells. Bioluminescent imaging of parasite replication showed that
all three compounds reduced the parasite burden in the murine model, with no apparent toxicity.
Leishmania major is the causative agent of cutaneous leishman-iasis (CL) disease (1). Worldwide, the incidence of CL is esti-
mated to be 0.7 to 1.2 million new cases per year (2). Other than
the drug miltefosine, which was approved by the FDA in 2014,
most of the currently used antileishmanial drugs were developed
in the 1940s (3, 4). However, drug-resistant strains of the parasite
have emerged. Furthermore, toxicity to the host and the high costs
of these drugs limit their wider application and use (4, 5). There-
fore, the burden of leishmaniasis and limited effective treatments
clearly point to the need for new drugs.
In view of the current interest in examining different antineo-
plastic agents for their antiprotozoal properties (6–8), we assessed
the antileishmanial activity of ,-unsaturated ketones (enones)
provided by J. R. Dimmock from the University of Saskatchewan
in Canada (1, 9). Enones react preferentially with cellular thiols, in
contrast to amino or hydroxyl functional groups present in pro-
tein and DNA (10, 11); therefore, interactions with nucleic acids,
which can lead to adverse genotoxic effects, should be absent in
enones (12). Since thiol-dependent metabolism is the main detox-
ifying mechanism in trypanosomatids, we hypothesized that
enones are attractive candidates for examination as potential
antileishmanial agents.
Hence, in this study, we screened the enone library for antipa-
rasitic and cytotoxic activity. The compounds were dissolved in
dimethyl sulfoxide (DMSO) and tested at concentrations ranging
from 500 M to 1 nM (1, 9). The parasites tested were a firefly
luciferase-expressing line ofL.majorpromastigotes described pre-
viously (Lmj-FV1-LUC-TK [L. major strain Friedlin {MHOM/JL/
80/Friedlin}], clone V1) and cultured as previously described (13,
14). The 126 enones were incubated with 106 L. major promasti-
gotes or rhesus monkey kidney epithelial cells (LLC-MK2)/well for
96 h and were analyzed for toxicity and parasite survival as mea-
sured by luciferase activity with the substrate 5=-fluoroluciferin
(ONE-Glo luciferase assay system; Promega) using a luminometer
(Luminoskan; Thermo Scientific). Sixty-four compounds inhib-
ited the survival of L. major promastigotes at75%. At the same
concentrations tested, 20 out of 126 screened compounds dis-
played minimal to no toxicity (75% survival) against LLC-MK2
cells. Only six compounds met the criteria for both antiparasitic
activity (25%) and low cytotoxicity to LLC-MK2 cells (75%)
(see Fig. S1 in the supplemental material). These six compounds
were further tested in the following mammalian cell lines: Hs27
human fibroblasts, RAW 264.7 murine macrophages (American
Type Culture Collection [ATCC], Manassas, VA), and peritoneal
BALB/c mice macrophages, obtained as described previously (15).
Only NC901, NC884, and NC2459 showed effective activity
against L. major. NC2459 showed a 100-fold difference between
the 50% effective concentration (EC50) of the parasite and that for
all three mammalian cell lines (Table 1).
The in vitro infectivity experiments were carried out to deter-
mine the activity of NC901, NC884, and NC2459 against L. major
intracellular amastigotes. Peritoneal macrophages isolated from
BALB/c mice were infected with L. major metacyclic promasti-
gotes for 24 h, followed by treatment with the NC lead compounds
for an additional 48 h (Table 1). The antileishmanial activity ex-
hibited by the compounds was evaluated using BD Pathway Bio-
imager high-content imaging assay (HCIA) analysis (16–18). In
comparison to the 1% DMSO control, all three compounds
showed a significant decrease in the percentage of infected cells.
NC2459 was the most effective at a concentration of 1.25 M
(Table 1).
Additionally, the activity of the compounds against L. major
was investigated in a murine model of CL. The first set of experi-
ments (Fig. 1A) consisted of 12 female BALB/c mice organized in
four groups of three, each infected with 105 L. major metacyclic
promastigotes (Table 2). As shown in Fig. 1A, at 46 days postin-
fection, all experimental groups exhibited a lesion size smaller
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than or equal to that of the group treated with amphotericin B.
Further support was obtained by determining the relative amount
of luminescence emitted from the luciferase-expressing parasites
in the infected footpad at the endpoint of the study, namely, 46
days postinfection (Fig. 1C). All mice in the NC2459 group did not
develop measurable lesions until 2 to 3 weeks after the last treat-
ment (total of 6 to 7 weeks postinfection). Furthermore, one out
of the three mice did not develop a lesion up to 12 weeks postin-
fection.
To determine the relative toxicity of the compounds, the
weights of the mice were measured twice a week (data not shown).
There was no significant weight loss for any of the groups except
for the mice receiving amphotericin B. Additionally, no mice died
as a result of the toxicity of the compounds.
Hyperinfection with L. major was tested. Twenty-six female
BALB/c mice organized in four groups of five and one group of six
mice were infected with 106 L. major metacyclic promastigotes
(Fig. 1B). All experimental groups were given higher doses than
the groups receiving 105 L. major metacyclic promastigotes (Table
2). At 4 weeks postinfection, the lesion size in all three NC com-
pounds significantly reduced in comparison to that of the diluent
control group (P 0.05). However, at 29 days postinfection, the
mice in the diluent control group had to be euthanized to avoid
physical distress caused by a large lesion; all other groups were
monitored for an additional 4 days. For this reason, the lumines-
cence from the infected footpads for each group was analyzed at 29
days postinfection and not at the endpoint of the experiment (Fig.
1D). After 1 week of treatment with NC2459, three of the mice
from this group were given double the daily dose of drug (8 mg/kg
of body weight/day), while the other three remained on the same
daily dose (4 mg/kg/day). In addition, the three mice given the
higher dose were treated with four additional doses. Those given
NC2459 (extended treatment) at 33 days postinfection showed a
smaller lesion than that of all the other groups (P  0.05). The
increase in dosage for NC2459 (extended treatment) did not result
in any additional weight loss or toxic side effects in comparison to
those of the control group. The procedures were performed to
minimize distress and pain for the animals according to NIH
guidance and the animal protocol approved by The University of
Texas at El Paso (UTEP) Institutional Animal Care and Use Com-
mittee (IACUC).
Our findings demonstrate the ability of these compounds to
reduce L. major replication in vivo without any obvious toxic side
effects. NC2459 evidently exhibited a much smaller amount of
swelling than that in all other groups by decreasing the footpad
lesion by 99.99% (Fig. 1A) in comparison with that of the diluent-
treated group. In summary, the data obtained in this study suggest
that our lead compound, NC2459, is an excellent antiparasitic
agent and might be useful as a potential alternative to the current
clinical drugs used to treat leishmaniasis. Clearly, NC2459 is an
important lead molecule, which is structurally divergent from
contemporary medications employed to treat parasitic diseases. It
is a prototypic molecule, and further molecular modifications are
required, followed by the relevant bioassays, to increase potency
and especially to increase the differential in toxicities between par-
asites and normal cells.
TABLE 1 Summary of EC50 and IC50 for NC901, NC884, and NC2459 tested against L. major and mammalian cells
a
Compound
Mammalian cell EC50 (M) SD for: L. major cells (M) (TI)
Peritoneal murine
macrophages LLC-MK2 Hs27 fibroblasts Promastigote EC50
Intracellular
amastigote IC50
7.03 0.42 8.02 0.25 16.0 0.12 0.45 (15.62) 1.87 0.20 (3.76)
7.67 0.31 15.1 0.33 16.3 0.17 1.12 (6.55) 0.937 0.13 (8.18)
5.45 0.36 2.0 0.093 10.01 0.09 0.020 (272.5) 0.625 0.11 (8.72)
a EC50, half-maximal effective concentration calculated with 95% confidence; IC50, 50% inhibitory concentration; TI, therapeutic index, calculated as (EC50 peritoneal murine
macrophages)/(EC50/IC50 parasites). The EC50 was obtained as the exponent of the negative ratio of the y-intercept and the slope of the fitted regression line (version 9.2; SAS
Software). P value,0.0001 for all concentrations. The Z-factor calculated for the HCIA is in the range of 0.5 to 0.91, indicating that the quality of the assay is excellent.
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